医学
美罗华
贝里穆马布
冷球蛋白血症
血管炎
内科学
胃肠病学
耐火材料(行星科学)
免疫学
丙型肝炎病毒
抗体
淋巴瘤
病毒
B细胞激活因子
疾病
B细胞
物理
天体生物学
作者
David Saadoun,Amine Ghembaza,Sébastien Rivière,A. Mékinian,Jonathan Boutémy,Gaëlle Leroux,F. Domont,Hélène Maillard,Mathieu Vautier,Patrice Cacoub
标识
DOI:10.1016/j.jaut.2020.102577
摘要
To report the efficacy of rituximab plus belimumab in patients with refractory cryoglobulinemia vasculitis (CV). Belimumab was administered intravenously at a dose of 10 mg/kg on days 0, 14, 28 and then every month in association with rituximab in 4 patients with refractory CV. Demographic, clinical and laboratory characteristics, treatment modalities and outcomes were recorded. All patients had type II IgM Kappa cryoglobulinemia, which was associated with primary Sjögren syndrome (n = 1), hepatitis C virus infection (n = 1), and essential (n = 2). Main manifestations of CV included purpura (n = 4), arthralgia and peripheral neuropathy (n = 3), and glomerulonephritis and skin ulcers (n = 1). In all cases, CV was refractory and/or relapse following rituximab. Intravenous belimumab infusion along with rituximab resulted in rapid clinical response in the four patients. Osteitis and recurrent urinary tract infections occurred in two patients. Belimumab along with rituximab showed promising results in refractory patients with CV.
科研通智能强力驱动
Strongly Powered by AbleSci AI